Lipocine Inc. (LPCN) stock
LPCNNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 9/3039% below fair value
$1.60−0.06 (-3.61%)
Close on Nov 17, 2026Market cap $13.19MP/E –Yield –
Lipocine price to sales ratio
The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.
Lipocine's price to sales ratio was 8.4× on Nov 11, 2026, against 4.3× a year earlier. Over the last 5 years it ranged from 1.5× to 376.0×, with a median of 11.6×.
Price to Sales Ratio at the end of each year
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| 2026 | Nov 11, 2026 | 8.4× | −1.7 |
| 2025 | Dec 31, 2025 | 10.1× | +6.8 |
| 2024 | Dec 31, 2024 | 3.3× | −239.5 |
| 2023 | Oct 31, 2023 | 242.8× | +237.9 |
| 2022 | Apr 29, 2022 | 4.8× | −121.5 |
| 2020 | Apr 30, 2020 | 126.4× | +68.0 |
| 2019 | Dec 31, 2019 | 58.4× | −6.4 |
| 2018 | Dec 31, 2018 | 64.8× | – |
See a number that looks wrong?